DK0652746T3 - Lymfatisk afgivelsessammensætning - Google Patents
Lymfatisk afgivelsessammensætningInfo
- Publication number
- DK0652746T3 DK0652746T3 DK93917936T DK93917936T DK0652746T3 DK 0652746 T3 DK0652746 T3 DK 0652746T3 DK 93917936 T DK93917936 T DK 93917936T DK 93917936 T DK93917936 T DK 93917936T DK 0652746 T3 DK0652746 T3 DK 0652746T3
- Authority
- DK
- Denmark
- Prior art keywords
- delivery composition
- lymphatic delivery
- lymphatic
- composition
- delivery
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6933—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained by reactions only involving carbon to carbon, e.g. poly(meth)acrylate, polystyrene, polyvinylpyrrolidone or polyvinylalcohol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Nanotechnology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Immunology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB929216082A GB9216082D0 (en) | 1992-07-28 | 1992-07-28 | Lymphatic delivery composition |
| PCT/GB1993/001596 WO1994002122A1 (en) | 1992-07-28 | 1993-07-28 | Lymphatic delivery composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0652746T3 true DK0652746T3 (da) | 1999-07-12 |
Family
ID=10719471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK93917936T DK0652746T3 (da) | 1992-07-28 | 1993-07-28 | Lymfatisk afgivelsessammensætning |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US5792475A (da) |
| EP (1) | EP0652746B1 (da) |
| JP (1) | JPH08501534A (da) |
| AU (1) | AU4717593A (da) |
| DE (1) | DE69321839T2 (da) |
| DK (1) | DK0652746T3 (da) |
| ES (1) | ES2124791T3 (da) |
| GB (2) | GB9216082D0 (da) |
| NO (1) | NO307169B1 (da) |
| WO (1) | WO1994002122A1 (da) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5346702A (en) * | 1992-12-04 | 1994-09-13 | Sterling Winthrop Inc. | Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization |
| US5439686A (en) * | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| US20070116761A1 (en) * | 1993-02-22 | 2007-05-24 | Desai Neil P | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US5981719A (en) | 1993-03-09 | 1999-11-09 | Epic Therapeutics, Inc. | Macromolecular microparticles and methods of production and use |
| US6090925A (en) | 1993-03-09 | 2000-07-18 | Epic Therapeutics, Inc. | Macromolecular microparticles and methods of production and use |
| US5543158A (en) * | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| US5565215A (en) * | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
| HUT75469A (en) * | 1994-02-28 | 1997-05-28 | Medinova Med Consulting Gmbh | Drug targeting system, method for preparing same and its use |
| US6007845A (en) * | 1994-07-22 | 1999-12-28 | Massachusetts Institute Of Technology | Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers |
| WO1996025918A1 (en) | 1995-02-24 | 1996-08-29 | Nanosystems L.L.C. | Aerosols containing nanoparticle dispersions |
| US5834025A (en) * | 1995-09-29 | 1998-11-10 | Nanosystems L.L.C. | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions |
| US5611344A (en) * | 1996-03-05 | 1997-03-18 | Acusphere, Inc. | Microencapsulated fluorinated gases for use as imaging agents |
| US6511477B2 (en) * | 1997-03-13 | 2003-01-28 | Biocardia, Inc. | Method of drug delivery to interstitial regions of the myocardium |
| US6443949B2 (en) * | 1997-03-13 | 2002-09-03 | Biocardia, Inc. | Method of drug delivery to interstitial regions of the myocardium |
| US8853260B2 (en) * | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US20030199425A1 (en) * | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
| US6369132B2 (en) * | 1997-10-17 | 2002-04-09 | Hercules Incorporated | Fine particle size low bulk density thermoplastic polymers |
| US6444192B1 (en) * | 1999-02-05 | 2002-09-03 | The Regents Of The University Of California | Diagnostic imaging of lymph structures |
| US6815170B1 (en) | 1999-06-30 | 2004-11-09 | John Wayne Cancer Institute | Methods for lymph node identification |
| AU5905400A (en) | 1999-07-14 | 2001-02-05 | Board Of Regents, The University Of Texas System | Methods and compositions for delivery and retention of active agents to lymph nodes |
| FR2835749B1 (fr) * | 2002-02-08 | 2006-04-14 | Inst Nat Sante Rech Med | Composition pharmaceutique ameliorant le transfert de gene in vivo |
| US20040197264A1 (en) * | 2003-04-04 | 2004-10-07 | Alexander Schwarz | Microspheres comprising therapeutic and diagnostic radioactive isotopes |
| CN101287507B (zh) * | 2005-08-12 | 2012-12-05 | 刘江 | 用于淋巴靶向的方法和装置 |
| AU2007285472B2 (en) * | 2006-03-30 | 2013-10-24 | Engene, Inc. | Non-viral compositions and methods for transfecting gut cells in vivo |
| WO2008022263A2 (en) * | 2006-08-17 | 2008-02-21 | Epix Pharmaceuticals, Inc. | Methods for lymph system imaging |
| WO2010102066A1 (en) | 2009-03-05 | 2010-09-10 | Bend Research, Inc. | Dextran polymer powder for inhalation administration of pharmaceuticals |
| WO2010138192A2 (en) | 2009-05-27 | 2010-12-02 | Selecta Biosciences, Inc. | Nanocarriers possessing components with different rates of release |
| CN102905728B (zh) | 2010-05-26 | 2015-11-25 | 西莱克塔生物科技公司 | 具有不偶合的佐剂的纳米载体组合物 |
| US8815294B2 (en) | 2010-09-03 | 2014-08-26 | Bend Research, Inc. | Pharmaceutical compositions of dextran polymer derivatives and a carrier material |
| US9060938B2 (en) | 2011-05-10 | 2015-06-23 | Bend Research, Inc. | Pharmaceutical compositions of active agents and cationic dextran polymer derivatives |
| US20130028857A1 (en) | 2011-07-29 | 2013-01-31 | Selecta Biosciences, Inc. | Synthetic nanocarriers comprising polymers comprising multiple immunomodulatory agents |
| US9687573B2 (en) | 2013-03-13 | 2017-06-27 | Biosphere Medical, Inc. | Compositions and associated methods for radioisotope-binding microparticles |
| CN111514317B (zh) * | 2020-04-09 | 2022-08-19 | 温州医科大学附属第一医院 | 一种淋巴系统双模态成像造影剂 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH652599A5 (de) * | 1981-08-28 | 1985-11-29 | Solco Basel Ag | Verfahren zur herstellung physiologisch abbaubarer kolloidaler, human-serumalbumin enthaltender produkte und ihre verwendung. |
| GB8601100D0 (en) * | 1986-01-17 | 1986-02-19 | Cosmas Damian Ltd | Drug delivery system |
| US5219577A (en) * | 1990-06-22 | 1993-06-15 | The Regents Of The University Of California | Biologically active composition having a nanocrystalline core |
| EP0654973A4 (en) * | 1992-07-21 | 1995-08-09 | Gen Hospital Corp | ARRANGEMENT FOR DELIVERING MEDICINES TO THE LYMPHIC TISSUE. |
| DE69327659T2 (de) * | 1992-10-14 | 2000-09-21 | Nycomed Imaging As, Oslo | Therapeutische und diagnostische bilderzeugungzusammensetzung und verfahren zur herstellung |
| US5336507A (en) * | 1992-12-11 | 1994-08-09 | Sterling Winthrop Inc. | Use of charged phospholipids to reduce nanoparticle aggregation |
| ATE156706T1 (de) * | 1993-03-17 | 1997-08-15 | Silica Gel Gmbh | Superparamagnetische teilchen, verfahren zu ihrer herstellung und verwendung derselben |
| US5565215A (en) * | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
| US5543158A (en) * | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| US5571536A (en) * | 1995-02-06 | 1996-11-05 | Nano Systems L.L.C. | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
| US5560931A (en) * | 1995-02-14 | 1996-10-01 | Nawosystems L.L.C. | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
-
1992
- 1992-07-28 GB GB929216082A patent/GB9216082D0/en active Pending
-
1993
- 1993-07-28 US US08/374,671 patent/US5792475A/en not_active Expired - Fee Related
- 1993-07-28 EP EP93917936A patent/EP0652746B1/en not_active Expired - Lifetime
- 1993-07-28 JP JP6504329A patent/JPH08501534A/ja active Pending
- 1993-07-28 AU AU47175/93A patent/AU4717593A/en not_active Abandoned
- 1993-07-28 ES ES93917936T patent/ES2124791T3/es not_active Expired - Lifetime
- 1993-07-28 DK DK93917936T patent/DK0652746T3/da active
- 1993-07-28 DE DE69321839T patent/DE69321839T2/de not_active Expired - Fee Related
- 1993-07-28 WO PCT/GB1993/001596 patent/WO1994002122A1/en not_active Ceased
- 1993-07-28 GB GB9500063A patent/GB2283422B/en not_active Expired - Fee Related
-
1995
- 1995-01-23 NO NO950238A patent/NO307169B1/no unknown
-
1998
- 1998-06-15 US US09/094,959 patent/US5928669A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| GB9216082D0 (en) | 1992-09-09 |
| NO307169B1 (no) | 2000-02-21 |
| JPH08501534A (ja) | 1996-02-20 |
| DE69321839D1 (de) | 1998-12-03 |
| DE69321839T2 (de) | 1999-04-15 |
| EP0652746B1 (en) | 1998-10-28 |
| NO950238D0 (no) | 1995-01-23 |
| AU4717593A (en) | 1994-02-14 |
| NO950238L (no) | 1995-01-23 |
| US5928669A (en) | 1999-07-27 |
| EP0652746A1 (en) | 1995-05-17 |
| GB2283422A (en) | 1995-05-10 |
| WO1994002122A1 (en) | 1994-02-03 |
| GB9500063D0 (en) | 1995-03-08 |
| ES2124791T3 (es) | 1999-02-16 |
| GB2283422B (en) | 1996-05-01 |
| US5792475A (en) | 1998-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2283422B (en) | Lymphatic delivery composition | |
| FI931738L (fi) | Teknisk harts-propenymppolymerkomposition | |
| DE69325158D1 (de) | Photokromische Zusammensetzung | |
| DE69316999D1 (de) | Abgabevorrichtung | |
| FI932957L (fi) | Glasfiberfoerstaerkt propenylpolymerkomposition | |
| NO930543D0 (no) | Doseringsform | |
| FI944793L (fi) | Sementtikoostumus | |
| DE69231784D1 (de) | Spenderanordnung | |
| FI930656L (fi) | Komposition foer nasal behandling | |
| DE69306691D1 (de) | Schalter | |
| NO933467D0 (no) | Ioderte aroyloksykarboksamider | |
| FI931161A0 (fi) | Kompositioner innehaollande estrar av karboxylhaltiga interpolymerer och anvaendning av dessa | |
| FI943612L (fi) | Annostelija | |
| ATE151296T1 (de) | Spritze | |
| DK65592D0 (da) | Forstoeverdyse | |
| DE69308385D1 (de) | Kunststoffzusammensetzung | |
| DE69225104D1 (de) | PCT-Zusammensetzung | |
| DE69304994D1 (de) | Tonartige Organopolysiloxanzusammensetzung | |
| DE59305564D1 (de) | Einspritzeinrichtung | |
| DE59301723D1 (de) | Schalter | |
| DE69217904D1 (de) | Zusammensetzung | |
| FI934387A0 (fi) | 3-substituerade 2-oxi-indol-1-karboxiamid omfattande farmaceutiska kompositioner | |
| DK0599461T3 (da) | Hærdelige sammensætninger | |
| DK155092D0 (da) | Dispenser | |
| DE69224296D1 (de) | Baumaschine |